Association of Plasma Angiogenin With Risk of Incident End-Stage Kidney Disease in Individuals With Type 2 Diabetes
Diabetes · 2025
DOI: 10.2337/db24-0699 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, 2025. Verfasst von Resham L Gurung und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Unit, Khoo Teck Puat Hospital, Singapore. Hauptthemen laut MEDLINE: Ribonuclease, Pancreatic, Diabetes Mellitus, Type 2, Kidney Failure, Chronic, Diabetic Nephropathies. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Khoo Teck Puat hospital, National Medical Research Council.
Themen: Diabetes mellitus
Abstract (Originalsprache)
We investigated the association between plasma angiogenin and the risk of progression to end-stage kidney disease (ESKD) in patients with type 2 diabetes (T2D) and attempted to infer the causal relationship between plasma angiogenin and chronic kidney disease. A total of 1,863 outpatients with T2D were included in this prospective cohort study. ESKD was defined as a composite of progression to sustained estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m2, maintenance dialysis, or death due to renal causes. The secondary outcome was rapid kidney function decline defined as a eGFR decline of 5 mL/min/1.73 m2 or greater per year. Over a median follow-up of 9.3 years, 125 incident ESKD events were identified. Elevated plasma angiogenin levels were associated with an increased risk of incident ESKD (adjusted hazard ratio 1.25 [95% CI 1.01–1.55], per 1 SD) independent of cardiorenal risk factors including baseline eGFR and albuminuria. A high level of plasma angiogenin was also associated with an increased risk for rapid kidney function decline (adjusted odds ratio 1.31 [95% CI 1.07–1.61], per 1 SD). A two-sample Mendelian randomization approach suggested a potential causal relationship between plasma angiogenin and chronic kidney disease. Plasma angiogenin may be a novel biomarker and potential therapeutic target for progressive kidney disease in patients with T2D. Article Highlights We investigated the association of plasma angiogenin with the risk of incident end-stage kidney disease (ESKD) in patients with type 2 diabetes. A high level of plasma angiogenin is independently associated with an increased risk for incident ESKD. A two-sample Mendelian randomization analysis suggested angiogenin may be causally involved in pathogenesis of chronic kidney disease. Plasma angiogenin may be a novel biomarker and potential therapeutic target for treatment of progressive kidney disease in patients with diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Research Unit, Khoo Teck Puat Hospital, Singapore.
- Cardiovascular and Metabolic Disorders Signature Research Program, Duke-NUS Medical School, Singapore.
- Saw Swee Hock School of Public Heath, National University of Singapore, Singapore.
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
ORCID-Profile: Su Chi Lim
Förderung
- Khoo Teck Puat hospital
- National Medical Research Council
Zitieren
APA
Gurung, R. L., Liu, J. J., Liu, S., Lee, J., Zheng, H., Chan, C., Ang, K., & Lim, S. C. (2025). Association of Plasma Angiogenin With Risk of Incident End-Stage Kidney Disease in Individuals With Type 2 Diabetes. Diabetes. https://doi.org/10.2337/db24-0699
Vancouver
Gurung RL, Liu JJ, Liu S, Lee J, Zheng H, Chan C, et al. Association of Plasma Angiogenin With Risk of Incident End-Stage Kidney Disease in Individuals With Type 2 Diabetes. Diabetes. 2025. doi:10.2337/db24-0699
BibTeX
@article{Gurung2025,
author = {Gurung, Resham L and Liu, Jian-Jun and Liu, Sylvia and Lee, Janus and Zheng, Huili and Chan, Clara and Ang, Keven and Lim, Su Chi},
title = {Association of Plasma Angiogenin With Risk of Incident End-Stage Kidney Disease in Individuals With Type 2 Diabetes},
journal = {Diabetes},
year = {2025},
doi = {10.2337/db24-0699}
}
EUVIMED